Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma PatientsValentina Marchica(University of Parma), Nicola Giuliani(University of Parma)CancersMarch 6, 201910.3390/cancers11030321Cited by 35SaveCiteExport RISWatch citationsRelated PapersDependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target|Blood|2016|172Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties|Oncotarget|2017|30PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients|Frontiers in Immunology|2021|20